{"id":"cabotegravir-tablets-for-oral-use","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypersensitivity reaction"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL2403238","moleculeType":"Small molecule","molecularWeight":"405.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabotegravir binds to the active site of HIV integrase and inhibits the strand transfer step of viral integration into the host genome. By blocking this critical step in the HIV replication cycle, the drug prevents establishment of persistent infection. It is a long-acting formulation designed for both oral and injectable administration.","oneSentence":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:36.589Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection treatment (in combination antiretroviral therapy)"},{"name":"HIV-1 pre-exposure prophylaxis (PrEP)"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT05514509","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-10-28","conditions":"HIV Infections","enrollment":370},{"nctId":"NCT07390409","phase":"","title":"ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.","status":"NOT_YET_RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2026-01-29","conditions":"HIV","enrollment":3700},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT06657885","phase":"PHASE2","title":"CAbotégravir LENacapavir DUal Long Acting","status":"WITHDRAWN","sponsor":"Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba","startDate":"2025-01-15","conditions":"HIV1 Infection, Multi-treated Patients Who Have Received Multiple Lines of Antiretroviral Treatment, CABOTEGRAVIR","enrollment":""},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT05374525","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-05-18","conditions":"HIV Infections","enrollment":287},{"nctId":"NCT03164564","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"HIV Infections","enrollment":3224},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT03299049","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2017-10-27","conditions":"HIV Infections","enrollment":1049},{"nctId":"NCT03739996","phase":"PHASE2","title":"Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-31","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT06807736","phase":"","title":"PrEPared to Choose (PtC) is an Implementation Study of the Delivery of Cabotegravir Long-acting, an Injectable Pre-exposure Prophylaxis (PrEP) Option for HIV Prevention. Injectable PrEP Will be Offered Alongside Oral and Vaginal Ring PrEP From Within a Real-world Context in Cape Town, South Africa.","status":"RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2024-02-13","conditions":"HIV Infection, Sexual and Reproductive Health","enrollment":1800},{"nctId":"NCT04824131","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-11-04","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT06485154","phase":"PHASE4","title":"Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2024-06-01","conditions":"HIV Prevention","enrollment":100},{"nctId":"NCT06138600","phase":"PHASE3","title":"Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Witwatersrand, South Africa","startDate":"2023-11-01","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT06405464","phase":"","title":"Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-03-01","conditions":"HIV Infections","enrollment":600},{"nctId":"NCT04399551","phase":"PHASE3","title":"A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-28","conditions":"HIV Infections","enrollment":437},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT04484337","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-07-31","conditions":"HIV Infections","enrollment":138},{"nctId":"NCT02178800","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-02","conditions":"HIV Infections","enrollment":199},{"nctId":"NCT03422172","phase":"PHASE1","title":"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-04-10","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT03149848","phase":"PHASE1","title":"Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":15},{"nctId":"NCT02354937","phase":"PHASE1","title":"Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-07-13","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":16},{"nctId":"NCT02354950","phase":"PHASE1","title":"A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-06-22","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT02478463","phase":"PHASE1","title":"Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-02-27","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":19},{"nctId":"NCT01641809","phase":"PHASE2","title":"Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-08-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":244},{"nctId":"NCT02076178","phase":"PHASE2","title":"Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-03-27","conditions":"Infection, Human Immunodeficiency Virus","enrollment":127},{"nctId":"NCT02462772","phase":"PHASE2","title":"Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa","status":"WITHDRAWN","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2015-10","conditions":"Human Immunodeficiency Virus","enrollment":""},{"nctId":"NCT02159131","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-08","conditions":"Infections, Human Immunodeficiency Virus and Hepatitis","enrollment":20},{"nctId":"NCT02027454","phase":"PHASE1","title":"Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":42},{"nctId":"NCT01593046","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":43},{"nctId":"NCT01848340","phase":"PHASE1","title":"An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-05","conditions":"HIV-associated Lipodystrophy Syndrome","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VOCABRIA"],"phase":"phase_3","status":"active","brandName":"Cabotegravir Tablets, for oral use.","genericName":"Cabotegravir Tablets, for oral use.","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA. Used for HIV-1 infection treatment (in combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}